Supplementary Figure 1.
Validation of PTEN immunohistochemistry.
a) Absence of PTEN expression in the LNCap prostate cancer cell line that has deletion of one allele and mutation in the second allele of PTEN. Note the lack of immunostaining in LNCap cells. b) Absence of PTEN expression in a prostate tumor. Note the staining of blood vessels (arrowheads), which serves as an internal control. c) Presence of PTEN expression in a prostate tumor. Note the staining of blood vessels (arrowheads), which serves as an internal control.

Figure 1.
PTEN and ERG immunohistochemistry from representative prostatectomy samples. PTEN and ERG scoring criteria defined: Absence of protein expression by immunohistochemistry for PTEN or ERG (i.e. score 0) was considered negative. Presence of staining (i.e. score +1 or +2 for PTEN; score +1 or +2 or +3 for ERG) was considered positive. Please see material and methods for detailed description.

Figure 2.
PTEN loss was associated with an increased risk of biochemical relapse with a median time to relapse of 19 months in the PTEN loss patients and 106 months in the PTEN normal patients (p = 0.01) with a hazard ratio (HR) of 2.47 for relapse in the PTEN loss group.